Dassault Systèmes to Acquire Medidata Solutions for $5.8 Billion to Accelerate Digital Transformation in Life Sciences

VCBeat (WeChat ID: vcbeat) learned from foreign media that on June 14, French technology company Dassault Systemes announced it would acquire health software company Medidata Solutions for $5.8 billion. The transaction has been unanimously approved by the boards of directors of both companies and is expected to be completed in the fourth quarter of this year.

Medidata Solutions is a leading enterprise in the digital transformation of the life sciences industry, dedicated to optimizing clinical development, commercialization, and real-world data intelligence. As of December 31, 2018, Medidata’s revenue for the previous fiscal year reached $636 million, with a net profit of $51.9 million. The company stated that 18 of the top 25 pharmaceutical companies and 9 of the top 10 contract research organizations (CROs) are its clients, and noted that 13 of the 15 best-selling drugs globally in 2018 utilized Medidata’s technology.

Medidata’s clinical expertise and cloud-based solutions support 1,300 clients worldwide—including pharmaceutical and biotechnology companies, contract research organizations (CROs), medical centers, and sites—in developing smarter therapeutic regimens and bringing them to commercialization. Its solutions enhance decision-making, accelerate process implementation, strengthen oversight, minimize operational risks, reduce costs, and optimize clinical trial protocols, thereby significantly improving the efficiency and quality of clinical development programs.

Tarek Sherif, Chairman of the Board, Co-Founder, and Chief Executive Officer of Medidata, stated: “Our mission is to deliver precision medicine to the patients who need it most at the most appropriate time. This mission has driven our innovation over the past 20 years and serves as the cornerstone of our commitment to the life sciences industry. We share the same vision, values, and passion with Dassault Systemes, and we will leverage our respective strengths to collaborate, utilizing an end-to-end business platform to advance the development of the life sciences industry.”

It is understood that Dassault Systemes began its commitment to the harmonious development of products, nature, and life in 2012. Since then, it has steadily advanced related knowledge and professional expertise, facilitating transformation in the product domain and expanding into collaborative, interdisciplinary biotech innovation. Dassault Systemes collaborates with 20 top global biopharmaceutical companies, hundreds of biotechnology firms, medical device manufacturers, research institutions, and government regulatory agencies to develop and launch innovative medical products and technologies, fully leveraging virtual world technologies to transform the patient experience.

“This represents a reasonable evolution of our business scope. Fundamentally, the life sciences sector itself is undergoing an accelerated digital transformation. This was the driving force behind Dassault Systemes’ acquisition of Medidata Solutions,” pointed out Bernard Charlès, Vice Chairman and CEO of Dassault Systemes. “Today, this acquisition marks a significant milestone for the life sciences industry, underscoring the immense value of the virtual world in developing complex personalized medicine and patient-centric experiences. Multidisciplinary technological innovation and industrial development require a platform-based approach that connects people, ideas, and data. We are now in a strong position to drive the transformation of the life sciences industry, which fully reflects Dassault Systemes’ mission to promote the harmonious development of products, nature, and life.”

Following the acquisition of Medidata, Dassault Systemes will further strengthen its position as a technology enterprise by providing an integrated business experience platform for the life sciences industry, supporting R&D, clinical trials, manufacturing, and the commercialization of new therapies and health technologies in an end-to-end manner.

(Compiled by: Zhang Jing)